Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Price Target at $53.88

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the eighteen ratings firms that are covering the company, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $53.88.

A number of equities analysts have issued reports on the stock. BTIG Research began coverage on shares of Kymera Therapeutics in a research report on Tuesday, December 10th. They issued a "buy" rating and a $60.00 price objective on the stock. Guggenheim boosted their price target on Kymera Therapeutics from $45.00 to $52.00 and gave the company a "buy" rating in a report on Friday, November 1st. Leerink Partners reaffirmed an "outperform" rating and set a $60.00 price target on shares of Kymera Therapeutics in a research report on Friday. Leerink Partnrs upgraded Kymera Therapeutics to a "strong-buy" rating in a research report on Monday, September 9th. Finally, Truist Financial reissued a "buy" rating and set a $53.00 target price (down from $54.00) on shares of Kymera Therapeutics in a research note on Friday, November 1st.

Institutional Trading of Kymera Therapeutics

A number of hedge funds have recently made changes to their positions in KYMR. JPMorgan Chase & Co. increased its position in Kymera Therapeutics by 212.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 140,491 shares of the company's stock valued at $6,649,000 after buying an additional 95,547 shares in the last quarter. Franklin Resources Inc. grew its stake in shares of Kymera Therapeutics by 35.1% in the third quarter. Franklin Resources Inc. now owns 29,440 shares of the company's stock worth $1,356,000 after acquiring an additional 7,647 shares during the last quarter. Wellington Management Group LLP increased its holdings in shares of Kymera Therapeutics by 7.2% during the third quarter. Wellington Management Group LLP now owns 4,618,359 shares of the company's stock valued at $218,587,000 after acquiring an additional 308,954 shares in the last quarter. Quarry LP purchased a new position in shares of Kymera Therapeutics in the 3rd quarter worth about $95,000. Finally, HighTower Advisors LLC bought a new position in Kymera Therapeutics in the 3rd quarter worth about $494,000.

Kymera Therapeutics Stock Performance

KYMR traded down $1.91 on Friday, hitting $40.11. 429,236 shares of the company were exchanged, compared to its average volume of 577,505. The firm has a fifty day simple moving average of $45.44 and a two-hundred day simple moving average of $43.54. The stock has a market capitalization of $2.60 billion, a PE ratio of -17.14 and a beta of 2.16. Kymera Therapeutics has a 12 month low of $22.35 and a 12 month high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.01. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The firm had revenue of $3.74 million for the quarter, compared to analysts' expectations of $10.34 million. During the same quarter last year, the business earned ($0.90) earnings per share. The business's revenue was down 20.9% on a year-over-year basis. On average, equities analysts expect that Kymera Therapeutics will post -2.79 earnings per share for the current year.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.